Sreedhara Alla, MD
Nephrology · Shreveport, LANPI 1215155791
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $527,171 of the $722,269 with a category attached, or 73.0%. 29 manufacturers reported payments, led by AstraZeneca at 38.3% of the total. Reporting peaked in 2022 at $220,312 and has fallen 60.6% since, to $86,850 in 2025. Among nephrology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,247 payments — averaging $579.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$277K
- Bayer$226K
- Aurinia Pharma U.S., Inc.$156K
- Travere Therapeutics, Inc.$36K
- Calliditas Therapeutics US Inc.$22K
- Amgen$1K
- plus $6K from 23 others
Across 162 payments — averaging $2753.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$291K
- AstraZeneca$92K
- Travere Therapeutics, Inc.$31K
- Ardelyx, Inc.$31K
What the payments were for
- Consulting fees$20,8503%
- Speaking & faculty fees$527,17173%
- Travel & lodging$146,14120%
- Food & beverage$27,4234%
- Education$6850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 420 | $276,710 |
| Bayer | 224 | $225,794 |
| Aurinia Pharma U.S., Inc. | 164 | $155,570 |
| Travere Therapeutics, Inc. | 72 | $35,625 |
| Calliditas Therapeutics US Inc. | 39 | $21,669 |
| Amgen(2 entities) | 53 | $1,121 |
| Fresenius USA Marketing, Inc. | 58 | $1,063 |
| GSK | 26 | $1,049 |
| Mallinckrodt Hospital Products Inc. | 33 | $757 |
| OPKO Pharmaceuticals, LLC | 41 | $604 |
| Otsuka America Pharmaceutical, Inc. | 24 | $537 |
| Akebia Therapeutics Inc | 26 | $491 |
| Daiichi Sankyo Inc. | 14 | $264 |
| Novartis | 13 | $243 |
| Novo Nordisk | 7 | $112 |
| Vifor Pharma, Inc. | 5 | $105 |
| Shire North American Group Inc | 5 | $93 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $77 |
| Boehringer Ingelheim | 4 | $64 |
| Scpharmaceuticals Inc. | 3 | $52 |
| Sanofi | 2 | $48 |
| ANI Pharmaceuticals, Inc. | 2 | $38 |
| Mallinckrodt Enterprises LLC | 2 | $37 |
| Recor Medical Inc | 2 | $36 |
| Ardelyx, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $18 |
| Veloxis Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$722,269 in reported general payments places this provider in the 95th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 112 | $106,831 |
| AuryxiaFerric Citrate | 43 | $71,419 |
| KerendiaFinerenone | 26 | $31,021 |
| TrulicityDulaglutide | 23 | $30,078 |
| RayaldeeCalcifediol | 21 | $28,778 |
| VelphoroSucroferric Oxyhydroxide | 12 | $22,410 |
| OzempicSemaglutide | 16 | $20,651 |
| LokelmaSodium Zirconium Cyclosilicate | 22 | $18,602 |
| JardianceEmpagliflozin | 15 | $17,827 |
| Sevelamer Carbonate | 90 | $10,831 |
| Calcitriol | 356 | $4,391 |
| Cinacalcet Hcl | 35 | $2,968 |
| Bumetanide | 50 | $1,506 |
| Olmesartan Medoxomil | 101 | $1,454 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 22 | $1,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $276,710 | $125,433134 claims |
| Akebia Therapeutics IncAuryxia | $491 | $71,41943 claims |
| BayerKerendia | $225,794 | $31,02126 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $604 | $28,77821 claims |
| Fresenius USA Marketing, Inc.Velphoro | $1,063 | $22,41012 claims |
| Novo NordiskOzempic | $112 | $20,65116 claims |
| Boehringer IngelheimJardiance | $64 | $17,82715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 nephrology providers in Louisiana.
Other nephrology in Shreveport
- Raja ZabanehShreveport$57K
- Kenneth AbreoShreveport$42K
- Neville DossabhoyShreveport$19K
- Marwan KaskasShreveport$18K
- Adrian SequeiraShreveport$18K
- Zulqarnain AbroShreveport$9K
- Cheng ChuShreveport$8K
- Arnold BarzShreveport$7K
- Srinivasa IskapalliShreveport$5K
- Adrian AbreoShreveport$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.